Evidence for humoral autoimmunity in neuromyelitis optica

Neurological Research

Volumn 28, Issue 3, 2006, Pages 348-353

  Wingerchuk, Dean M ^a  

^a MAYO CLINIC   (United States)

Author keywords

Antibodies; Cellular; Immunity; Neuromyelitis optica; Pathogenesis

Indexed keywords

AQUAPORIN 4; AUTOANTIBODY; AZATHIOPRINE; BIOLOGICAL MARKER; COMPLEMENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; GLATIRAMER; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERFERON BETA SERINE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB;

ANTIBODY BLOOD LEVEL; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CENTRAL NERVOUS SYSTEM DISEASE; COMPLEMENT ACTIVATION; DEMYELINATING DISEASE; DISEASE ASSOCIATION; HUMAN; HUMORAL IMMUNITY; IDIOPATHIC DISEASE; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; PLASMAPHERESIS; REVIEW; TREATMENT INDICATION;

ANIMALS; AQUAPORIN 4; AUTOANTIBODIES; AUTOIMMUNITY; HUMANS; IMMUNOTHERAPY; NEUROMYELITIS OPTICA;

EID: 33646797000     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164106X98260     Document Type: Review

References (36)

1. Cree BA, Goodin DS, Hauser SL. Neuromyelitis optica. Semin Neurol 2002; 22 (2): 105-122
2. de Seze J. Neuromyelitis optica. Arch Neurol 2003; 60 (9): 1336-1338
3. Wingerchuk DM. Neuromyelitis optica: Current concepts. Front Biosci 2004; 9: 834-840
4. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23: 683-747
5. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 2004; 364 (9451): 2106-2112
6. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202 (4): 473-477
7. Allbutt TC. On the ophthalmoscopic signs of spinal disease. Lancet 1870; 1: 76-78
8. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. In: McDonald WI, Noseworthy JH, eds. Multiple Sclerosis 2, 2nd edn, Woburn, MA, USA: Butterworth-Heinemann, 2003: pp. 243-258
9. O'Riordan JI, Gallagher HL, Thompson AJ, et al. Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry 1996; 60 (4): 382-387
10. Wingerchuk DM, Hogancamp WF, O'Brien PC, et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999; 53 (5): 1107-1114
11. Wingerchuk DM, Pittock SJ, Lennon VA, et al. Neuromyelitis optica diagnosis criteria revisited: Validation and incorporation of the NMO-IgG serum autoantibody. Neurology 2005; 64 (Suppl. 1): A38
12. Boumpas DT, Patronas NJ, Dalakas MC, et al. Acute transverse myelitis in systemic lupus erythematosus: Magnetic resonance imaging and review of the literature. J Rheumatol 1990; 17 (1): 89-92
13. Manabe Y, Sasaki C, Warita H, et al. Sjogren's syndrome with acute transverse myelopathy as the initial manifestation. J Neurol Sci 2000; 176 (2): 158-161
14. Hummers LK, Krishnan C, Casciola-Rosen L, et al. Recurrent transverse myelitis associates with anti-Ro (SSA) autoantibodies. Neurology 2004; 62 (1): 147-149
15. Weinshenker BG, Vukusic S, Wingerchuk DM, et al. NMO-IgG predicts relapse in patients with longitudinally extensive idiopathic transverse myelitis. Neurology 2005; 64 (Suppl. 1): A128
16. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002; 125 (Pt 7): 1450-1461
17. Ortiz de Zarate JC, Tamaroff L, Sica RE, et al. Neuromyelitis optica versus subacute necrotic myelitis. II. Anatomical study of two cases. J Neurol Neurosurg Psychiatry 1968; 31 (6): 641-645
18. Lefkowitz D, Angelo JN. Neuromyelitis optica with unusual vascular changes. Arch Neurol 1984; 41 (10): 1103-1105
19. Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 2000; 47 (6): 707-717
20. Nakashima I, Fujihara K, Fujimori J, et al. Absence of IgG1 response in the cerebrospinal fluid of relapsing neuromyelitis optica. Neurology 2004; 62 (1): 144-146
21. Correale J, Fiol M. Activation of humoral immunity and eosinophils in neuromyelitis optica. Neurology 2004; 63 (12): 2363-2370
22. Agre P, Kozono D. Aquaporin water channels: Molecular mechanisms for human diseases. FEBS Lett 2003; 555 (1): 72-78
23. Gold R, Linington C. Devic's disease: Bridging the gap between laboratory and clinic. Brain 2002; 125 (Pt 7): 1425-1427
24. Storch MK, Stefferl A, Brehm U, et al. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 1998; 8 (4): 681-694
25. Nielsen S, Nagelhus EA, Amiry-Moghaddam M, et al. Specialized membrane domains for water transport in glial cells: High-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J Neurosci 1997; 17 (1): 171-180
26. Wingerchuk DM, Weinshenker BG. Neuromyelitis Optica. Curr Treat Options Neurol 2005; 7 (3): 173-182
27. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: Clinical predictors of a relapsing course and survival. Neurology 2003; 60 (5): 848-853
28. Bot JC, Barkhof F, Polman CH, et al. Spinal cord abnormalities in recently diagnosed MS patients: Added value of spinal MRI examination. Neurology 2004; 62 (2): 226-233
29. Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46 (6): 878-886
30. Keegan M, Pineda AA, McClelland RL, et al. Plasma exchange for severe attacks of CNS demyel'mation: Predictors of response. Neurology 2002; 58 (1): 143-146
31. Keegan M, Konig F, McClelland R, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005; 366 (9485): 579-582
32. Saida T, Tashiro K, Itoyama Y, et al. Interferon beta-1b is effective in Japanese RRMS patients: A randomized, multicenter study. Neurology 2005; 64 (4): 621-630
33. Yong VW, Chabot S, Stuve O, et al. Interferon beta in the treatment of multiple sclerosis: Mechanisms of action. Neurology 1998; 51 (3): 682-689
34. Neuhaus O, Farina C, Wekerle H, et al. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 2001; 56 (6): 702-708
35. Mandler RN, Ahmed W, Dencoff JE. Devic's neuromyelitis optica: A prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998; 51 (4): 1219-1220
36. Cree BA, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005; 64 (7): 1270-1272